Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(5 years from now) | |
US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(7 months ago) | |
US8309112 | ENDO PHARMS | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
Feb, 2023
(7 months ago) | |
US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(7 months ago) | |
US7276250 | ENDO PHARMS | Sustained release formulations of oxymorphone |
Feb, 2023
(7 months ago) | |
US8075872 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
US8309060 | ENDO PHARMS | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(10 months from now) | |
US8192722 | ENDO PHARMS | Abuse-proof dosage form |
Sep, 2025
(1 year, 11 months from now) | |
US8808737 | ENDO PHARMS | Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment |
Jun, 2027
(3 years from now) |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: Relief of moderate to severe pain; Dose modification for renal impairment
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic